FENTON DENNIS M 4
4 · First Tracks Biotherapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
First Tracks (TRAX) Director Dennis Fenton Receives 6,030 Shares
What Happened
Dennis M. Fenton, a director of First Tracks Biotherapeutics, had 6,030 restricted stock units (RSUs vest) convert to 6,030 shares on June 15, 2026. The Form 4 shows an exercise/conversion of a derivative (code M) acquiring 6,030 shares at $0.00 and a corresponding derivative disposition entry; no cash was paid and no open‑market sale is reported.
Key Details
- Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely filing).
- Reported prices: $0.00 per share (RSU settlement for no consideration). Total reported cash value: $0.
- Shares affected: 6,030 RSUs converted to 6,030 common shares.
- Shares owned after transaction: not specified in the provided excerpt of the filing.
- Footnotes: F1 notes each RSU converts to one share for no consideration; F2 states 100% of the RSUs vested on June 15, 2026, subject to continued service.
- Transaction code: M (exercise or conversion of a derivative instrument — here RSU settlement).
Context
RSU vesting is a compensation event that converts restricted units into stock and is not the same as a market purchase or sale; it does not by itself signal a buy or sell decision. The filing shows conversion of compensation awards into shares rather than an open‑market trade.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-06-15+6,030→ 10,995 total - Exercise/Conversion
Restricted Stock Unit
[F1][F2]2026-06-15−6,030→ 0 total→ Common Stock (6,030 underlying)
Footnotes (2)
- [F2]The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F1]Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.